3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
2
Gynecologic
2
Genitourinary
2
Gastrointestinal
2
Breast
2
Thoracic
1
NET
1
Lymphoid
1
Head & Neck
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Neoplasms by Site
3
Neoplasms
3
Lymphoma, Large-Cell, Anaplastic
3
Neoplasms by Histologic Type
2
Lymphoproliferative Disorders
2
Hematologic Neoplasms
2
Carcinoma, Renal Cell
2
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Melanoma
1
Lymphoma
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Colonic Diseases
1
Cholangiocarcinoma
1
Interventions
Magnetic Resonance Spectroscopy
6
Cyclophosphamide
6
X-Rays
5
Phantoms, Imaging
5
Filgrastim
5
pembrolizumab
4
Specimen Handling
4
Radiotherapy
4
Nuclear Medicine Department, Hospital
4
Gemcitabine
4
Biopsy
4
tazemetostat
3
Surveys and Questionnaires
3
Psychiatric Rehabilitation
3
Etoposide
3
Drug Therapy
3
Carboplatin
3
Busulfan
3
Bevacizumab
3
ulixertinib
2
tipifarnib
2
spartalizumab
2
selpercatinib
2
palbociclib
2
olaparib
2
larotrectinib
2
ivosidenib
2
ganitumab
2
ensartinib
2
aflibercept
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
alectinib
×
Lymphoid
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts